Trial name | Year | Intervention and control settings | Participants’ characteristics | Key results and findings |
---|---|---|---|---|
Malignant melanoma | ||||
dacarbazine + ipilimumab versus dacarbazine + placebo (NCT00324155) [338] | 2011 | First line dacarbazine + ipilimumab versus dacarbazine | N = 502; median age = 57 yr; 65 years: 32% | OS ≥ 65 yr, HR: 0.99 (0.56–1.25); OS < 65 yr, HR: 0.67 (0.40–0.87) |
KEYNOTE-006 (NCT01866319) [339] | 2015 | First line or pretreated pembrolizumab versus ipilimumab | N = 834; median age = 62 yr; 65 years: 43% | OS ≥ 65 yr, HR: 0.56 (0.36–0.87); OS < 65 yr, HR: 0.65 (0.44–0.95) |
CheckMate 066 (NCT01721772) [340] | 2014 | First line nivolumab versus dacarbazine | N = 418; median age = 65 yr; 65 years: 52% | OS ≥ 75 yr, HR: 0.25 (0.10–0.61); OS 65–74 yr, HR: 0.44 (0.24–0.81); OS < 65 yr, HR: 0.52 (0.32–0.85) |
CheckMate 067 (NCT01844505) [341] | 2017 | First line nivolumab + ipilimumab versus ipilimumab versus nivolumab | N = 945; median age = 60 yr; 65 years: 40% | OS ≥ 65 yr, HR: 0.69; OS < 65 yr, HR: 0.48 (n + i vs. i); OS ≥ 65 yr, HR: 0.96; OS < 65 yr, HR: 0.78 (n + i vs. n); OS ≥ 65 yr, HR: 0.71; OS < 65 yr, HR: 0.62 (n vs. i) |
CheckMate 238 (NCT02388906) [342] | 2017 | Adjuvant nivolumab versus ipilimumab | N = 906; median age = 55 yr; 65 years: 26% | RFS ≥ 65 yr, HR: 0.66 (0.45–0.97); RFS < 65 yr, HR: 0.65 (0.51–0.84) |
KEYNOTE-054 (NCT02362594) [343] | 2018 | Adjuvant pembrolizumab versus placebo | N = 1019; median age = 54 yr; 65 years: 25% | RFS ≥ 65 yr, HR: 0.55 (0.32–0.93); RFS < 65 yr, HR: 0.57 (0.41–0.80) |
Non-small cell lung cancer | ||||
KEYNOTE-024 (NCT02142738) [344] | 2016 | First line, TPS > 50%, pembrolizumab versus platinum-based chemotherapy | N = 305; median age = 65 yr; 65 years: 54% | OS ≥ 65 yr, HR: 0.64 (0.42–0.98); OS < 65 yr, HR: 0.60 (0.38–0.96) |
KEYNOTE-042 (NCT02220894) [345] | 2019 | First line, TPS > 1%, pembrolizumab versus platinum-based chemotherapy | N = 1274; median age = 63 yr; 65 years: 45% | OS ≥ 65 yr, HR: 0.82 (0.66–1.01); OS < 65 yr, HR: 0.81 (0.67–0.98) |
KEYNOTE-010 (NCT01905657) [346] | 2016 | Pretreated, pembrolizumab versus docetaxel | N = 1034; median age = 63 yr; 65 years: 41% | OS ≥ 65 yr, HR: 0.76 (0.57–1.02); OS < 65 yr, HR: 0.63 (0.50–0.79) |
CheckMate 017 (NCT01642004) [347] | 2015 | Pretreated squamous, nivolumab versus docetaxel | N = 272; median age = 63 yr; 65 years: 44% | OS ≥ 75 yr, HR: 1.85 (0.76–4.51); OS 65–74 yr, HR: 0.56 (0.34–0.91); OS < 65 yr, HR: 0.52 (0.35–0.75) |
CheckMate 057 (NCT01673867) [348] | 2015 | Pretreated non squamous, nivolumab versus docetaxel | N = 582; median age = 62 yr; 65 years: 42% | OS ≥ 75 yr, HR: 0.90 (0.43–0.87); OS 65–74 yr, HR: 0.63 (0.45–0.89); OS < 65 yr, HR: 0.81 (0.62–1.04) |
OAK (NCT02008227) [349] | 2017 | Pretreated, atezolizumab versus docetaxel | N = 850; median age = 64 yr; 65 years: 47% | OS ≥ 65 yr, HR: 0.66 (0.52–0.83); OS < 65 yr, HR: 0.80 (0.64–1.00) |
PACIFIC (NCT02125461) [350] | 2017 | Adjuvant concurrent chemoradiotherapy followed by durvalumab versus placebo | N = 709; median age = 64 yr; 65 years: 45% | OS ≥ 65 yr, HR: 0.76 (0.55–1.06); OS < 65 yr, HR: 0.62 (0.44–0.86) |
KEYNOTE-189 (NCT02578680) [351] | 2018 | First line non squamous, cisplatin or carboplatin + pemetrexed + pembrolizumab versus cisplatin or carboplatin + pemetrexed | N = 616; median age = 64 yr; 65 years: 49% | OS ≥ 65 yr, HR: 0.64 (0.43–0.95); OS < 65 yr, HR: 0.43 (0.31–0.61) |
KEYNOTE-407 (NCT02775435) [352] | 2018 | First line squamous, carboplatin + paclitaxel + pembrolizumab | N = 559; median age = 65 yr; 65 years: 55% | OS ≥ 65 yr, HR: 0.74 (0.51–1.07); OS < 65 yr, HR: 0.52 (0.34–0.80) |
CheckMate 227 (NCT02477826) [353] | 2019 | First line, TPS > 1%, nivolumab + ipilimumab versus platinum-based chemotherapy | N = 1189; median age = 64 yr; 65 years: 49% | OS ≥ 75 yr, HR: 0.92 (0.57–1.48); OS 65–74 yr, HR: 0.91 (0.70–1.19); OS < 65 yr, HR: 0.70 (0.55–0.89) |
CheckMate 9LA (NCT03215706) [354] | 2021 | First line nivolumab + ipilimumab + platinum-based chemotherapy versus platinum-based chemotherapy | N = 719; median age = 65 yr; 65 years: 51% | OS ≥ 75 yr, HR: 1.21; OS 65–74 yr, HR: 0.62; OS < 65 yr, HR: 0.61 |
IMpower150 (NCT02366143) [355] | 2018 | First line or post-TKI non squamous carboplatin + paclitaxel + bevacizumab + atezolizumab versus carboplatin + paclitaxel + bevacizumab | N = 800; median age = 63 yr; 65 years: 45% | PFS ≥ 75 yr, HR: 0.78; PFS 65–74 yr, HR: 0.52; PFS < 65 yr, HR: 0.65 |
IMpower010 (NCT02486718) [356] | 2021 | resected IB-IIIA with chemotherapy followed by atezolizumab versus BSC | N = 1005; median age = 62 yr; 65 years: 67% | DFS ≥ 65 yr, HR: 0.76 (0.54–1.05); DFS < 65 yr, HR: 0.79 (0.61–1.03) |
Renal cell carcinoma | ||||
CheckMate 025 (NCT01668784) [357] | 2015 | Pretreated nivolumab versus everolimus | N = 821; median age = 62 yr; 65 years: 39% | OS ≥ 75 yr, HR: 1.23 (0.66–2.31); OS 65–74 yr, HR: 0.64 (0.45–0.91); OS < 65 yr, HR: 0.78 (0.60–1.01) |
CheckMate 214 (NCT02231749) [358] | 2018 | First line nivolumab + ipilimumab versus sunitinib | N = 1096; median age = 62 yr; 65 years: 38% | OS ≥ 75 yr, HR: 0.97 (0.48–1.95); OS 65–74 yr, HR: 0.86 (0.58–1.27); OS < 65 yr, HR: 0.53 (0.40–0.71) |
KEYNOTE-426 (NCT02853331) [359] | 2019 | First line pembrolizumab + axitinib versus sunitinib | N = 861; median age = 62 yr; 65 years: 38% | OS ≥ 65 yr, HR: 0.59 (0.36–0.97); OS < 65 yr, HR: 0.47 (0.30–0.73) |
JAVELIN 101 (NCT02684006) [360] | 2019 | First line avelumab + axitinib versus sunitinib | N = 886; median age = 61 yr; 65 years: 38% | PFS ≥ 65 yr, HR: 0.70 (0.49–0.99); PFS < 65 yr, HR: 0.68 (0.54–0.87) |
Urothelial carcinoma | ||||
KEYNOTE-045 (NCT02256436) [361] | 2017 | Pretreated pembrolizumab versus investigator choice chemotherapy | N = 542; median age = 66 yr; 65 years: 58% | OS ≥ 65 yr, HR: 0.76 (0.56–1.02); OS < 65 yr, HR: 0.75 (0.53–1.05) |
IMvigor-130 (NCT02807636) [362] | 2020 | First line platinum-based chemotherapy + atezolizumab versus platinum-based chemotherapy | N = 1231; median age = 68 yr; 65 years: 63% | PFS ≥ 65 yr, HR: 0.80 (0.66–0.97); PFS < 65 yr, HR: 0.82 (0.63–1.06) |
JAVELIN 100 (NCT02603432) [363] | 2020 | first line maintenance avelumab + BSC versus BSC | N = 700; median age = 69 yr; 65 years: 66% | OS ≥ 65 yr, HR: 0.63 (0.47–0.83); OS < 65 yr, HR: 0.79 (0.55–1.15) |